Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia.

[1]  M. Remberger,et al.  Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. , 2003, Tissue antigens.

[2]  T. Klingebiel,et al.  Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL , 2002, Leukemia.

[3]  D. Wall,et al.  Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. , 2002, Blood.

[4]  M. Remberger,et al.  The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. , 2001, Blood.

[5]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[6]  M. Remberger,et al.  Treatment of severe acute graft‐versus‐host disease with anti‐thymocyte globulin , 2001, Clinical transplantation.

[7]  M. Remberger,et al.  Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting , 2000, Bone Marrow Transplantation.

[8]  O. Ringdén,et al.  Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia , 2000, Bone Marrow Transplantation.

[9]  M. Remberger,et al.  A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation , 1999, Bone Marrow Transplantation.

[10]  M. Remberger,et al.  Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation , 1999, Bone Marrow Transplantation.

[11]  Wan Ariffin Bin Abdullah,et al.  Med Pediatr Oncol , 1999 .

[12]  R. Martuza,et al.  Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. , 1999, Human gene therapy.

[13]  T. Polyak,et al.  Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis. , 1997, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  M. G. Bhat,et al.  Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. , 1997, The Journal of investigative dermatology.

[15]  Robert H. Collins,et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Labopin,et al.  The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Leukemia & lymphoma.

[17]  M. Labopin,et al.  Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 1996, Bone marrow transplantation.

[18]  L. Soroceanu,et al.  The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Nagler,et al.  Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT. , 1996, Blood.

[20]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[21]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[22]  P. Ljungman,et al.  Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. , 1995, Bone marrow transplantation.

[23]  J. Dinulos,et al.  Graft-versus-host disease in children. , 1995, Seminars in dermatology.

[24]  J. Aschan.  Treatment of moderate to severe acute graft-versus-host disease: a retrospective analysis. , 1994, Bone marrow transplantation.

[25]  P. Ljungman,et al.  A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. , 1994, Blood.

[26]  G. Dini,et al.  Graft-versus-host disease in children: the AIEOP-BMT Group experience with cyclosporin A. , 1993, Bone marrow transplantation.

[27]  H. Deeg,et al.  Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? , 1993, Blood.

[28]  O. Olerup,et al.  HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. , 1992, Tissue antigens.

[29]  A. Rimm,et al.  T-cell depletion of HLA-identical transplants in leukemia. , 1991, Blood.

[30]  A. Rimm,et al.  Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. , 1991, Bone marrow transplantation.

[31]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[32]  G. Janossy,et al.  Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. , 1991, Bone marrow transplantation.

[33]  G. Gahrton,et al.  Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. , 1991, Bone marrow transplantation.

[34]  A. Rimm,et al.  Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.

[35]  James,et al.  Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. , 1989, Blood.

[36]  O. Ringdén,et al.  Pretransplant herpesvirus serology and acute graft-versus-host disease. , 1988, Transplantation.

[37]  A I Goldman,et al.  Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  T. Stijnen,et al.  HERPES-VIRUS IMMUNITY AND ACUTE GRAFT-VERSUS-HOST DISEASE , 1987, The Lancet.

[39]  R. Gale,et al.  GRAFT REJECTION AND GRAFT-VERSUS-HOST DISEASE: MIRROR IMAGES , 1986, The Lancet.

[40]  G. Gahrton,et al.  A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. , 1986, Bone marrow transplantation.

[41]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[42]  R. Storb,et al.  Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.

[43]  S. Slavin,et al.  Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. , 1984, Journal of immunology.

[44]  Buckner Cd,et al.  MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKAEMIA , 1982, The Lancet.

[45]  K. Sullivan,et al.  Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. , 1981, The New England journal of medicine.

[46]  A. Rimm,et al.  Bone marrow transplantation for acute leukemia. , 1979, JAMA.

[47]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[48]  Parry Rh.  Health centres of today; Bristol. , 1946 .

[49]  D. Pfaff,et al.  Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats , 2005, Journal of Neuro-Oncology.

[50]  S. Singhal,et al.  Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? , 2002, Bone Marrow Transplantation.

[51]  M. Remberger,et al.  The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  E. Farmer,et al.  Methoxsalen and ultraviolet A radiation in treatment of chronic cutaneous graft-versus-host reaction. , 1985, Journal of the American Academy of Dermatology.

[53]  H. Deeg,et al.  Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. , 1985, Medical and pediatric oncology.

[54]  B. Johansson,et al.  Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. , 1983, Acta radiologica. Oncology.

[55]  D. Cox.  Regression Models and Life-Tables , 1972 .